A cross-sectional epidemiological study of hidradenitis
suppurativa in an Irish population (SHIP)
AbbVie Limited, Dublin, Ireland
Department of Dermatology, St Vincent’s University Hospital, Dublin, Ireland
Department of Dermatology, South Inﬁrmary Victoria University Hospital, Cork, Ireland
Department of Dermatology, Adelaide and Meath Hospital, Dublin, Ireland
Department of Dermatology, University Hospital Galway, Galway, Ireland
*Correspondence: E. Delany. E-mail: firstname.lastname@example.org
Background Hidradenitis suppurativa (HS), a chronic inﬂammatory disease that affects apocrine gland–bearing skin,
has a signiﬁcant impact on patients’ quality of life. Estimates of the epidemiologic prevalence of HS are highly variable,
and clinical data on disease characteristics and patient burden of disease remain limited.
Objective The primary objective of this study was to determine the number of patients with HS attending dermatology
clinics in a hospital setting in Ireland (within a 6-month time period). Secondary objectives included the assessment of
disease characteristics and the collection of patient responses on disease burden and work productivity.
Methods This was an epidemiologic, non-interventional, cross-sectional study across four dermatology clinics in Ireland
over a 6-month time period. The disease prevalence was estimated by calculating the percentage of total patients with a
diagnosis of HS (the primary population) across the selected sites. Secondary analyses were performed using the full anal-
ysis set, which consisted of eligible adults (≥18 years of age) from the primary population who provided informed consent.
Data from these analyses are presented as descriptive summary statistics, with the use of an analysis of covariance for
Results The prevalence of HS across the four selected sites was estimated at 1.4% (95% CI, 1.24–1.62). One hundred
and ﬁfty eligible patients comprised the full analysis set. The majority of participants were white (95.3%), female
(70.0%), cigarette smokers (56.0%) and overweight or obese (body mass index ≥25 kg/m
, 81.8%). Most patients for
whom data were available presented with Hurley stage II (50.4%), and more than a third of the full analysis set had a rela-
tive with HS (34.7%). Questionnaire responses revealed a profound impact on quality of life, including diminished work
productivity and various psychological comorbidities.
Conclusion This study offers insight into the clinical features and disease burden of hidradenitis suppurativa in an Irish
Received: 5 July 2017; Accepted: 20 October 2017
Conﬂicts of interest
The design, study conduct, and ﬁnancial support for the study were provided by AbbVie. AbbVie participated in the
interpretation of data, review and approval of the manuscript. Emma Delany and Gemma Gormley are employees
of AbbVie and may own AbbVie stock or options. Professor Brian Kirby has received research support from
AbbVie, Janssen, MSD, Novartis and Pﬁzer, and has served as a consultant and/or received Honoraria from
Abbott, AbbVie, Celgene, Eli Lilly, Janssen, MSD, Novartis and Pﬁzer. Dr Trevor Markham has received research
support from AbbVie and Pﬁzer; has served as a consultant and/or received Honoraria from Abbott, AbbVie,
Janssen, Novartis and Pﬁzer; and has served as a consultant to AbbVie in the conduct of the SHIP study. Dr
Michelle Murphy has served as a consultant to AbbVie in the conduct of the SHIP study and has received research
funding for the SHIP study from AbbVie. Dr Anne-Marie Tobin has served on advisory boards for AbbVie, Janssen,
Leo Pharma, Novartis and Pﬁzer, and has received unrestricted grant funding from AbbVie, Merck Serono and
Pﬁzer. Dr Rosalind Hughes, Dr Shivashini Kirthi and Dr Siobhan McCarthy have no conﬂict of interests to declare.
© 2017 The Authors. Journal of European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venerology.
2018, 32, 467–473
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.